Trajectory-Image 2 (1)

Company Milestones

Every Step Counts

We are proud of the milestones we have accomplished since our founding in 2016. Each step forward is a step closer to our goal to improve healthcare through better disease detection.


BillionToOne was founded


Rented half of a bench at Start X

September 2018

Received a National Institutes of Health grant for the first single-gene NIPT clinical study with Baylor University

Jan 2019

Moved to the first non-shared lab with six employees

March 2019

BillionToOne Closes $15 Million Series A Funding

June 2019

Achieved Clinical Laboratory Improvement Amendments (CLIA) certification

July 2019

Received the first UNITY commercial sample

October 2019

Published first single-gene NIPT validation study in Nature Scientific Reports

July 2020

Launched UNITY aneuploidy and RhD tests

April 2021

Moved into lab 2.0

June 2021

BillionToOne Closes $55M Series B Funding

March 2022

BillionToOne Closes $125M Series C Funding

April 2022

Published single-gene NIPT health economics study in Journal of Health Economics

April 2022

Hired 200th employee

May 2022

Achieved College of American Pathologists (CAP) Lab Accreditation Program Certification

May 2022

Published single-gene NIPT sickle cell disease data in the American Journal of Hematology

June 2022

Northstar Select and Response launched for research use only (RUO)

September 2022

Launched UNITY fetal antigen NIPT for alloimmunized pregnant patients

November 2022

Published first clinical outcomes study in Genetics in Medicine showing high accuracy of single-gene NIPT

December 2022

Announced $48.5M additional capital raise and $35M upsized term loan facility

January 2023

Northstar Select and Response CLIA launch

January 2023

Northstar Select and Response launched for clinical use

August 2023

BillionToOne Publishes UNITY Fetal RhD and Fetal Antigen NIPT Clinical Validity Demonstrating >99.9% Accuracy

October 2023

BillionToOne Announces Clinical Outcomes Data for UNITY Fetal Risk™ Screen, Demonstrating Exceptional Accuracy in General Pregnancy Population

December 2023

BillionToOne Announces Global Collaboration to Provide its UNITY Fetal Antigen™ Clinical Trial Assay in Johnson & Johnson Phase 3 Clinical Trial of Nipocalimab in Hemolytic Disease of the Fetus and Newborn

April 2024

UNITY Complete helps over 80,000 Pregnant Patients Determine Need for Anti-D Immune Globulin